Concepts (106)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiosurgery | 4 | 2024 | 106 | 1.010 |
Why?
|
Pain | 2 | 2012 | 470 | 0.550 |
Why?
|
Carcinoma, Renal Cell | 2 | 2024 | 237 | 0.520 |
Why?
|
Bone Neoplasms | 2 | 2012 | 426 | 0.510 |
Why?
|
Kidney Neoplasms | 2 | 2024 | 430 | 0.450 |
Why?
|
Urology | 2 | 2024 | 74 | 0.430 |
Why?
|
Rectal Neoplasms | 2 | 2016 | 77 | 0.430 |
Why?
|
Professional Practice Location | 1 | 2012 | 7 | 0.410 |
Why?
|
Professional Practice | 1 | 2012 | 42 | 0.400 |
Why?
|
Radiation Oncology | 1 | 2012 | 23 | 0.400 |
Why?
|
Radiotherapy, Computer-Assisted | 1 | 2009 | 3 | 0.340 |
Why?
|
Tomography, Spiral Computed | 1 | 2009 | 16 | 0.340 |
Why?
|
Radiotherapy, Conformal | 1 | 2009 | 55 | 0.330 |
Why?
|
Health Services Accessibility | 1 | 2012 | 594 | 0.280 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2012 | 1114 | 0.250 |
Why?
|
Delphi Technique | 1 | 2024 | 200 | 0.210 |
Why?
|
Metformin | 1 | 2023 | 148 | 0.190 |
Why?
|
Consensus | 1 | 2024 | 612 | 0.180 |
Why?
|
Carcinoma, Small Cell | 1 | 2019 | 49 | 0.160 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2009 | 68 | 0.160 |
Why?
|
Head and Neck Neoplasms | 1 | 2023 | 482 | 0.160 |
Why?
|
Acute Lung Injury | 1 | 2018 | 62 | 0.150 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2020 | 234 | 0.140 |
Why?
|
Lung Injury | 1 | 2018 | 118 | 0.140 |
Why?
|
Colonic Neoplasms | 1 | 2019 | 247 | 0.130 |
Why?
|
Hospitals, Public | 1 | 2016 | 38 | 0.130 |
Why?
|
Time Factors | 4 | 2016 | 6201 | 0.130 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2020 | 651 | 0.120 |
Why?
|
Transurethral Resection of Prostate | 1 | 2014 | 4 | 0.120 |
Why?
|
Urination Disorders | 1 | 2014 | 17 | 0.120 |
Why?
|
Prognosis | 3 | 2019 | 4508 | 0.120 |
Why?
|
Time-to-Treatment | 1 | 2016 | 186 | 0.120 |
Why?
|
Urethra | 1 | 2014 | 83 | 0.110 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2014 | 143 | 0.110 |
Why?
|
Radiation Injuries | 1 | 2014 | 142 | 0.100 |
Why?
|
Group Practice | 1 | 2012 | 11 | 0.100 |
Why?
|
Geographic Information Systems | 1 | 2012 | 40 | 0.100 |
Why?
|
Ownership | 1 | 2012 | 30 | 0.100 |
Why?
|
Survival Rate | 2 | 2019 | 1995 | 0.100 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 426 | 0.090 |
Why?
|
Cranial Irradiation | 1 | 2010 | 69 | 0.090 |
Why?
|
Femur Head | 1 | 2009 | 6 | 0.090 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2009 | 71 | 0.080 |
Why?
|
Body Height | 1 | 2010 | 210 | 0.080 |
Why?
|
Pelvis | 1 | 2009 | 68 | 0.080 |
Why?
|
Rectum | 1 | 2009 | 98 | 0.080 |
Why?
|
Chemoradiotherapy | 2 | 2020 | 101 | 0.080 |
Why?
|
Humans | 13 | 2024 | 123177 | 0.080 |
Why?
|
Urinary Bladder | 1 | 2009 | 242 | 0.080 |
Why?
|
Texas | 2 | 2016 | 3548 | 0.070 |
Why?
|
Hydroxycholecalciferols | 1 | 2006 | 6 | 0.070 |
Why?
|
Intestine, Small | 1 | 2009 | 302 | 0.070 |
Why?
|
Imaging, Three-Dimensional | 1 | 2009 | 359 | 0.070 |
Why?
|
Brachytherapy | 2 | 2020 | 74 | 0.070 |
Why?
|
Computer Simulation | 1 | 2009 | 637 | 0.070 |
Why?
|
Receptors, Calcitriol | 1 | 2006 | 72 | 0.070 |
Why?
|
Prostatic Neoplasms | 1 | 2014 | 1515 | 0.060 |
Why?
|
Palliative Care | 1 | 2008 | 428 | 0.060 |
Why?
|
Neoplasm Staging | 2 | 2019 | 1216 | 0.060 |
Why?
|
Neoplasms | 1 | 2018 | 2767 | 0.060 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 804 | 0.050 |
Why?
|
Europe | 1 | 2024 | 376 | 0.050 |
Why?
|
Receptors, Estrogen | 1 | 2006 | 789 | 0.050 |
Why?
|
Follow-Up Studies | 1 | 2012 | 5047 | 0.050 |
Why?
|
Neoplasm Metastasis | 1 | 2024 | 649 | 0.050 |
Why?
|
Antineoplastic Agents | 2 | 2020 | 1677 | 0.040 |
Why?
|
Cisplatin | 1 | 2020 | 242 | 0.040 |
Why?
|
Drug Therapy | 1 | 2019 | 87 | 0.040 |
Why?
|
Radiotherapy | 1 | 2019 | 139 | 0.040 |
Why?
|
Disease Progression | 1 | 2024 | 2027 | 0.040 |
Why?
|
General Surgery | 1 | 2019 | 203 | 0.030 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 1240 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2006 | 2483 | 0.030 |
Why?
|
Urogenital System | 1 | 2014 | 34 | 0.030 |
Why?
|
Databases, Factual | 1 | 2019 | 1169 | 0.030 |
Why?
|
Retrospective Studies | 2 | 2023 | 15979 | 0.030 |
Why?
|
Prostatic Hyperplasia | 1 | 2014 | 106 | 0.030 |
Why?
|
Treatment Outcome | 1 | 2009 | 12102 | 0.030 |
Why?
|
Quality Indicators, Health Care | 1 | 2016 | 214 | 0.030 |
Why?
|
Constriction, Pathologic | 1 | 2014 | 238 | 0.030 |
Why?
|
Quality of Health Care | 1 | 2016 | 391 | 0.030 |
Why?
|
Prospective Studies | 1 | 2023 | 6028 | 0.030 |
Why?
|
Male | 4 | 2024 | 60015 | 0.030 |
Why?
|
Disease Management | 1 | 2016 | 516 | 0.020 |
Why?
|
Aged | 2 | 2020 | 19065 | 0.020 |
Why?
|
Laser Therapy | 1 | 2014 | 246 | 0.020 |
Why?
|
Middle Aged | 2 | 2020 | 25973 | 0.020 |
Why?
|
Adult | 2 | 2020 | 29032 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2019 | 6368 | 0.020 |
Why?
|
Female | 3 | 2020 | 65423 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2014 | 2838 | 0.020 |
Why?
|
Young Adult | 1 | 2019 | 8865 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2006 | 1063 | 0.020 |
Why?
|
Transfection | 1 | 2006 | 1068 | 0.010 |
Why?
|
Cell Cycle | 1 | 2006 | 611 | 0.010 |
Why?
|
United States | 1 | 2019 | 10618 | 0.010 |
Why?
|
Receptors, Progesterone | 1 | 2006 | 865 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2006 | 713 | 0.010 |
Why?
|
Gene Expression | 1 | 2006 | 1569 | 0.010 |
Why?
|
Risk Factors | 1 | 2014 | 10001 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2006 | 2307 | 0.010 |
Why?
|
Animals | 1 | 2018 | 33732 | 0.010 |
Why?
|
Infant | 1 | 2010 | 12321 | 0.010 |
Why?
|
Child, Preschool | 1 | 2010 | 13859 | 0.010 |
Why?
|
Adolescent | 1 | 2010 | 19083 | 0.010 |
Why?
|
Child | 1 | 2010 | 24205 | 0.010 |
Why?
|